A case of rifampicin induced pseudomembraneous colitis.
We report a case pf pseudomembranous colitis that developed in a patient with tuberculous abdominal lymphadenopathy during treatment with rifampicin. The patient had delayed presentation (3 months) after the start of rifampicin. She had one relapse after 2 months that was successfully treated, and she finished her antituberculosis therapy without any further relapses. Awareness of this serious complication of rifampicin therapy should be encountered.
Akbar
Daad H
DH
Department of Medicine, King Abdul-Aziz University Hospital, Jeddah, Kingdom of Saudi Arabia. daadakb@yahoo.com
Al-Shehri
Halia Z
HZ
Al-Huzali
Amani M
AM
Falatah
Hind I
HI
D015746:Abdominal Pain / Q000175:diagnosis / Q000209:etiology; D000328:Adult; D001707:Biopsy, Needle; D003113:Colonoscopy / Q000379:methods; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004761:Enterocolitis, Pseudomembranous / Q000139:chemically induced* / Q000188:drug therapy / Q000473:pathology*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007150:Immunohistochemistry; D008795:Metronidazole / Q000627:therapeutic use; D012293:Rifampin / Q000009:adverse effects* / Q000627:therapeutic use; D016896:Treatment Outcome; D014388:Tuberculosis, Lymph Node / Q000175:diagnosis / Q000188:drug therapy
D008795:Metronidazole; D012293:Rifampin